CTS (CTS) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
29 Apr, 2026Business overview and market positioning
Designs and manufactures custom engineered solutions for sensing, connectivity, and motion across global markets, with $555M in LTM revenue and 23% adjusted EBITDA margin.
Revenue is diversified: 43% transportation, 26% industrial, 16% medical, and 15% aerospace & defense.
Global footprint with 58% of sales in North America, 21% in Europe, and 21% in Asia.
Focuses on automation, healthcare innovation, sustainability, and electrification as key growth drivers.
Growth strategy and execution
Targets 10% annual growth through a mix of organic initiatives and strategic M&A.
Leverages deep technical expertise and long-standing customer relationships to drive mid-single digit organic growth.
Strategic M&A enhances technology, expands product lines, and strengthens customer relationships, contributing ~5% of sales growth.
Strong balance sheet and cash flow support ongoing investments and acquisitions.
End market performance and innovation
Industrial market LTM revenue at $145M (+14% YOY), driven by automation and sustainability trends.
Medical market LTM revenue at $90M (+25% YOY), with growth in ultrasound and wireless pacemaker applications.
Aerospace & defense LTM revenue at $84M (+15% YOY), benefiting from increased defense spending and EU expansion.
Transportation LTM revenue at $236M, with >95% of portfolio powertrain agnostic and new product awards secured.
Latest events from CTS
- Strong growth and innovation in sensing and motion solutions drive 10% annual revenue targets.CTS
Investor presentation - Record Q2 2026 margins, 7% revenue growth, and raised outlook driven by diversified markets.CTS
Q2 2026 - Medical, industrial, and defense growth outpace automotive, with strong margins and disciplined M&A.CTS
16th Annual East Coast IDEAS Conference - Q1 2026 delivered 11% sales growth, margin expansion, and robust earnings improvement.CTS
Q1 2026 - 2025 saw diversified growth, strong cash flow, and continued focus on governance and ESG.CTS
Proxy filing - Votes will be cast on directors, executive pay, and auditor ratification at the 2026 meeting.CTS
Proxy filing - Q4 revenue up 9% with strong diversified growth; 2026 outlook remains positive.CTS
Q4 2025 - Q3 2024 saw higher margins and EPS, with diversified growth offsetting transportation declines.CTS
Q3 2024 - Q2 2024 sales fell 10% year-over-year, but net income and defense diversification improved.CTS
Q2 2024